[go: up one dir, main page]

GB202315831D0 - Treatment of skin disease - Google Patents

Treatment of skin disease

Info

Publication number
GB202315831D0
GB202315831D0 GBGB2315831.4A GB202315831A GB202315831D0 GB 202315831 D0 GB202315831 D0 GB 202315831D0 GB 202315831 A GB202315831 A GB 202315831A GB 202315831 D0 GB202315831 D0 GB 202315831D0
Authority
GB
United Kingdom
Prior art keywords
treatment
skin disease
disease
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2315831.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB2315831.4A priority Critical patent/GB202315831D0/en
Publication of GB202315831D0 publication Critical patent/GB202315831D0/en
Priority to PCT/IB2024/060077 priority patent/WO2025083540A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB2315831.4A 2023-10-16 2023-10-16 Treatment of skin disease Ceased GB202315831D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2315831.4A GB202315831D0 (en) 2023-10-16 2023-10-16 Treatment of skin disease
PCT/IB2024/060077 WO2025083540A1 (en) 2023-10-16 2024-10-15 Treatment of skin disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2315831.4A GB202315831D0 (en) 2023-10-16 2023-10-16 Treatment of skin disease

Publications (1)

Publication Number Publication Date
GB202315831D0 true GB202315831D0 (en) 2023-11-29

Family

ID=88863652

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2315831.4A Ceased GB202315831D0 (en) 2023-10-16 2023-10-16 Treatment of skin disease

Country Status (2)

Country Link
GB (1) GB202315831D0 (en)
WO (1) WO2025083540A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2009KN02655A (en) 2003-12-10 2015-10-23 Medarex Inc
RU2412202C2 (en) 2004-06-21 2011-02-20 Медарекс, Инк. Antibodies of interferon alfa receptor 1 and their application
MX2010008578A (en) 2008-02-08 2010-11-10 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity.
SMT201700063T1 (en) 2009-09-03 2017-03-08 Medimmune Llc Type 1 interferon diagnostic
FI3769781T3 (en) 2015-08-19 2023-06-07 Astrazeneca Ab STABLE ANTI-IFNAR1 FORMULATION
CN106243226B (en) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 The antibody and application thereof of anti-human IFNAR1
DK4114465T5 (en) 2021-04-23 2024-07-22 Astrazeneca Ab ANTI-IFNAR1 DOSAGE SCHEDULE FOR SUBCUTANEOUS INJECTION
AU2022261422A1 (en) * 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of cutaneous lupus erythematous

Also Published As

Publication number Publication date
WO2025083540A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
IL321560A (en) Treatment of autoimmune disease
IL304628A (en) Treatment of skin disorders
CA223399S (en) Skin treatment tip
GB202315831D0 (en) Treatment of skin disease
GB202001353D0 (en) Treatment of skin conditions
IL307205A (en) Peri-lesional treatment of skin conditions
GB202404416D0 (en) Treatment of disease
LT4313114T (en) Combined treatment of brain injury
GB202503453D0 (en) Compounds for the treatment of skin diseases
GB202403324D0 (en) Compounds for the treatment of skin diseases
GB202216028D0 (en) Methods of treatment of melanocytic disease
GB202206359D0 (en) Treatment of pain
GB202301306D0 (en) Treatment of granulomatous disease
GB202418867D0 (en) Skin treatment
CA3280366A1 (en) Peptides for treatment of skin disease
CA234057S (en) Skin treatment tip
CA229136S (en) Skin treatment tip
CA212940S (en) Skin massager
CA212939S (en) Skin massager
GB202116774D0 (en) Treatment of pain
AU2021903178A0 (en) Treatment of VEGFA-Related Disease
GB202116795D0 (en) Treatment of visceral pain
GB2618915B (en) Treatment of cardiovascular disease
AU2020903576A0 (en) Treatment of VEGFA-Related Disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)